MDXH

MDxHealth SA (MDXH) - Form 20-F Summary

Business Context and Reporting Period

Company: MDxHealth SA (Belgian company, listed on Nasdaq Capital Market under symbol MDXH).
Reporting Period: Fiscal year ended December 31, 2024.
Business Overview: A commercial-stage precision diagnostics company providing non-invasive, clinically actionable urologic solutions, primarily for prostate cancer (Select mdx, Confirm mdx, Genomic Prostate Score/GPS) and urinary tract infections (Resolve mdx). The company operates CLIA-certified laboratories in Irvine, California, and Plano, Texas.

Key Financial Metrics (Year Ended Dec 31, 2024)

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 28% year-over-year, driven primarily by increased volumes of tissue-based tests (Confirm mdx and GPS), which comprised 80% of total revenue.
• Expense Increases: Research and Development (R&D) expenses rose 65% to $10.6 million due to increased clinical study costs. Selling and Marketing expenses increased 11% to $41.0 million, largely due to incentive compensation tied to revenue growth.
• Debt Restructuring: In May 2024, the company entered a new $100 million senior secured credit facility with OrbiMed, replacing the previous Innovatus facility. $55 million was drawn in May 2024, and an additional $25 million was drawn in March 2025 (subsequent event).
• Equity Financing: In September and October 2024, the company completed a registered public offering raising approximately $44.4 million in gross proceeds.
• Financial Expenses: Financial expenses decreased 16% to $15.3 million, primarily due to decreases in fair-value adjustments for GPS contingent consideration, partially offset by interest charges on the new OrbiMed facility and debt extinguishment costs.

Guidance, Outlook, and Risks

• Going Concern: Management expects to continue incurring net losses and significant cash outflows for at least the next 12 months. While the company has sufficient cash to meet requirements for the next 12 months, continued profitability is not guaranteed.
• Debt Covenants: The OrbiMed Credit Agreement includes restrictive covenants, including minimum net revenue requirements and minimum unrestricted cash levels (temporarily reduced to $12.5 million through Dec 31, 2024). Failure to meet these could trigger repayment acceleration.
• Contingent Consideration: The company has a potential earnout liability of up to $82.5 million payable to Exact Sciences based on GPS revenue milestones for fiscal years 2023-2025. As of Dec 31, 2024, the fair value of this liability was approximately $67.3 million.
• Regulatory Risks: The company faces uncertainty regarding the FDA's "LDT Rule" (Laboratory Developed Tests), which may require pre-market review for its tests starting in 2027/2028, potentially increasing costs and delaying commercialization.
• Reimbursement: Revenue is heavily dependent on reimbursement from Medicare (approx. 41% of 2024 revenue) and commercial payors. Changes in coverage policies could materially impact financial results.

Key Facts for Investor Verification

• Liquidity Position: Verify the company's ability to maintain the minimum unrestricted cash covenant ($12.5 million through end of 2024, then $20 million) required by the OrbiMed credit facility.
• Debt Service: Confirm the interest rate structure (SOFR + 8.50% or 2.50% + 8.50%, whichever is greater) and the impact of potential revenue shortfalls triggering mandatory principal repayments.
• GPS Earnout: Monitor GPS revenue performance against the milestones required to trigger the up to $82.5 million earnout payment to Exact Sciences.
• Regulatory Compliance: Assess the impact of the FDA's LDT Rule implementation timeline on the company's current test portfolio and future R&D costs.
• Revenue Concentration: Note that 80% of revenue is derived from two tissue-based tests (Confirm mdx and GPS), creating concentration risk.